（N，N-二乙基-4-亚硝基苯胺HYDROCHLOR＆） | 4673-18-1

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 石蒜科生物碱
• 中文名称: （N，N-二乙基-4-亚硝基苯胺HYDROCHLOR＆）
• 英文名称: Buphanitine
• 英文别名: (1S,13R,15R,17R)-9-methoxy-5,7-dioxa-12-azapentacyclo[10.5.2.01,13.02,10.04,8]nonadeca-2,4(8),9-triene-15,17-diol
• CAS: 4673-18-1
• 化学式: C₁₇H₂₁NO₅
• 分子量: 319.4
• InChiKey: KCNHESDRNJNLEV-PGCOIXJOSA-N

物化性质

• 熔点：
  232°
• 比旋光度：
  D20 -102° (c = 1 in chloroform)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  71.4
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Compounds and compositions for treating infection
  申请人：Chepkwony Paul Kiprono

  公开号：US20090069277A1

  公开（公告）日：2009-03-12

  Compounds from 14 Kenyan plants, including from the root of Dovyalis abyssinica and Clutia robusta have been characterized and isolated, and their uses are disclosed.

  来自14种肯尼亚植物的化合物，包括 Dovyalis abyssinica 和 Clutia robusta 的根部已经被鉴定和分离，它们的用途也被公开了。
• COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION
  申请人：Chepkwony Paul Kiprono

  公开号：US20120190734A1

  公开（公告）日：2012-07-26

  Compounds from 14 Kenyan plants, including from the root of Dovyalis abyssinica and Clutia robusta have been characterized and isolated, and their uses are disclosed.

  来自14种肯尼亚植物的化合物已经被鉴定和分离，包括来自阿比西尼亚多维亚利斯和强健小簇花的根部，它们的用途已经被披露。
• COMPOSITIONS FOR DELIVERY OF BIOLOGICAL AGENTS AND METHODS FOR THE PREPARATION THEREOF
  申请人：UNIVERSITY OF NEBRASKA BOARD OF REGENTS

  公开号：EP1005324B1

  公开（公告）日：2005-03-30
• EP1005324A4
  申请人：——

  公开号：EP1005324A4

  公开（公告）日：2001-06-06
• Supramolecular Complexes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
  申请人：Hardy Charles Thomas

  公开号：US20080299177A1

  公开（公告）日：2008-12-04

  Targeted therapeutic delivery systems comprising specially designed nanocarriers for intracellular therapeutic delivery, mediated by acoustic energy, for use either in vivo or in vitro, are described. Nanocarriers comprised of substantially supramolecular complexes, and mixtures thereof, are used to treat a variety of diseases in humans and other species, such as cancer, opthalmological, pulmonary, urinary or other pathologies. Methods for preparing the targeted therapeutic delivery systems are also embodied, which comprise processing a solution comprised of biopolymers or other species and components, with or without targeting moieties, adding said biopolymers and other compounds to a solution containing one or more therapeutic agents, stabilizing or not stabilizing said nanocarriers, adding one or more contrast agents, and resulting in a targeted therapeutic delivery system. Preferred therapeutics for use with the present invention include nucleic acids, proteins, peptides, and other therapeutic macromolecules.